Tuberous Sclerosis Complex Clinical Trial
Official title:
Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex
The investigators are running an intervention study for young children with Tuberous
Sclerosis Complex (TSC). The study will include free play-based behavioral intervention that
may improve social and communication skills in children with TSC. Eligible families will have
a child in the age range of 12-36 months, with a diagnosis of TSC. A parent must also be
available to attend the weekly intervention sessions at UCLA.
The intervention will focus on teaching caregivers skills to improve the social and
communication outcomes of their children. The content of the intervention will be
individually tailored to the child's developmental level. The intervention involves
pre-assessments, an intervention period of daily 60 minute sessions for 10 days, followed by
weekly 60 minute sessions for 10 weeks, and post-assessments. The classroom can have up to 3
parent-child dyad and the curriculum focuses on improving social-communication and play
skills.
Most children with Tuberous Sclerosis Complex (TSC) suffer from neurodevelopmental
disabilities, including intellectual disability (ID) and autism spectrum disorder (ASD).
There is a tremendous need for early intervention for all infants with TSC, with a focus on
improving non-verbal cognition and social communication skills. However, no studies have
investigated whether early intervention can improve social communication skills in infants
with TSC. As a result, families of infants with TSC struggle to receive adequate
interventions targeting these areas of development.
The investigators propose to enroll 32 infants and toddlers with TSC to study an
evidence-based behavioral intervention in infants with TSC, combining the efforts of
investigators with expertise in autism intervention, infant development, and TSC. The
proposed intervention study adapts a parent-mediated treatment called JASPER (Joint
attention, symbolic play, engagement, regulation) that has successfully improved social
communication outcomes in toddlers and young children with ASD.
JASPER intervention will last 3 months, and is split into two phases. Phase 1 occurs for the
first 2 weeks of intervention, and consists of daily 1 hour intervention sessions (Monday
through Friday) for 2 weeks. After Phase 1, Phase two begins, and consists of 60 minute
sessions once a week for 10 weeks. Participants will receive behavioral assessments and EEG
across 4 assessment time points during this study: At the start of participation in the
study, two weeks into participation of the study, 3 months into participation of the study,
and 6 months into participation in the study. The behavioral assessments administered
throughout these time points will measure social communication skills, overall cognitive
functioning, and non-verbal communication. EEG is sensitive to subtle changes in the brain
and may be able to capture responses to treatment prior to clinical or behavioral change, and
can inform researchers of the brain basis for the behavioral changes found with intervention.
The EEG at each time point will be 30-45 minutes in length, and will require the participant
to be awake, as they will watch several short videos on a tv screen while recording EEG data.
There are 2 randomized participation groups in this study, Treatment Group 1, and Treatment
Group 2. Treatment group 1 will begin JASPER intervention immediately, and thus will complete
the first 3 assessment time points while in intervention, and the 4th assessment time point 3
months after intervention ends. Treatment Group 2 will complete the 4 assessment time points
while receiving services as usual in the community, and will begin intervention after the 4th
assessment time point. Treatment group 1 will participate in this study for a total of 6
months, and treatment group 2 will participate in the study for a total of 9 months, since
they will receive services in the community as usual for 6 months before beginning the 3
month intervention. Group assignment is randomized, and each participant has an equal chance
of being assigned to either treatment group.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
Completed |
NCT02201212 -
Everolimus for Cancer With TSC1 or TSC2 Mutation
|
Phase 2 | |
Completed |
NCT01767779 -
Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
|
||
Recruiting |
NCT05104983 -
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
|
Phase 2 | |
Recruiting |
NCT02098759 -
Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex
|
N/A | |
Recruiting |
NCT01730209 -
Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex
|
Phase 2/Phase 3 | |
Recruiting |
NCT03356769 -
Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
|
Phase 2 | |
Recruiting |
NCT04987463 -
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
|
Phase 2/Phase 3 | |
Completed |
NCT05323370 -
Lymphangioleiomyomatosis, a Study on Cathepsin K
|
||
Recruiting |
NCT06392009 -
A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05604170 -
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
|
Phase 3 | |
Completed |
NCT03276195 -
Studies in Patients With Tuberous Sclerosis Complex
|
||
Recruiting |
NCT05059327 -
Basimglurant in Children, Adolescents, and Young Adults With TSC
|
Phase 2 | |
Completed |
NCT02061397 -
Safety of Simvastatin in LAM and TSC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04112537 -
Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
|
||
Active, not recruiting |
NCT02962414 -
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
|
Phase 3 | |
Active, not recruiting |
NCT05495425 -
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
|
Phase 3 | |
Active, not recruiting |
NCT05044819 -
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
|
Phase 4 | |
Completed |
NCT01929642 -
Rapalogues for Autism Phenotype in TSC: A Feasibility Study
|
Phase 2 | |
Recruiting |
NCT06160310 -
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
|